Featured Story

  • Gene variant linked to a 10-year delay in Alzheimer's onset

    By studying a group of outliers in a Colombian family known for the prevalence of early-onset Alzheimer's, investigators at UC Santa Barbara believe they may have fingered a new drug target that could delay the disease by a decade or more.

New research highlights role of SKA2 gene in PTSD, suicide

A year ago, researchers at Johns Hopkins concluded that chemical alterations in the SKA2 gene appeared to be linked with a higher risk for suicide. And now another team has followed up, exploring biomarkers from the change-up in the SKA2 gene that could also be used to identify who might be most at risk for post-traumatic stress disorder, or PTSD.

Mouse study suggests Prozac may help stroke patients recover

Researchers in the neurology department at Johns Hopkins have shown that a generic selective serotonin reuptake inhibitor may help human stroke victims.

Eta-amyloid discovered in Alzheimer's adds new piece to the complex puzzle

Alzheimer's disease is often characterized by the appearance of protein aggregates that are toxic in the brain. For over 30 years it has been known that protein fragments called beta-amyloid peptides generate these insoluble deposits. Now researchers have characterized a new protein aggregate at play that needs to be carefully considered by Alzheimer's drug investigators.

TGen IDs targets for nonalcoholic fatty liver disease

Researchers at the Translational Genomics Research Institute (TGen) say they have identified a potential gene associated with the initiation of nonalcoholic fatty liver disease, the most common cause of liver damage.

MSK: 'This is what the future of precision medicine looks like'

Investigators at Memorial Sloan Kettering Cancer Center have changed the rules of the clinical trial game in the first of what they say will be a new wave of studies that examine a drug's potential based on a broad patient population who share the same genetic mutation rather than cancer type.


From Our Sister Sites


C.R. Bard is facing pushback over one of its blood-clot devices, as reports surface that the company's product caused serious injuries--and in some cases, death--in patients, and that Bard allegedly tried to sweep the problems under the rug.


The MD Anderson Cancer Center in Houston is becoming the preferred partner of choice among a growing group of immuno-oncology players looking to develop a new generation of drugs. This afternoon it was Cellectis' turn to join the migration south, sayings its researchers in New York will be working with some of the top experts at MD Anderson as the biotech advances a group of off-the-shelf CAR-T cell therapies.